United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bioline RX

BioNTech SE

Canadian Solar

Danaos

Global Ship Lease

Jumia

Goldman Sachs JUST US Large Cap Equity ETF

Lithium Americas Corp

VanEck Rare Earth/Strategic Metals ETF

SSR Mining

Universal Insurance Hlds

Viatris

Zogenix

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

2021 Top Idea Contest - New Ideas

These are Insider's biggest healthcare stories for July 29.

Pfizer says its shot protection wanes after 6 months

The company posted great Q2 results. But its future prospects look even brighter than it's saying.

Why Pfizer's Q2 Update Was Even Better Than You Might Think

Pfizer Inc. (PFE) CEO Albert Bourla on Q2 2021 Results - Earnings Call Transcript

Ford Motor Company

Microsoft

Tilray Brands

Shopify

Ford, Shopify, Microsoft, Pfizer and Tilray were our top stock trades for Thursday. That said, let's get a look at the charts now.

5 Top Stock Trades for Thursday: F, SHOP, MSFT, PFE, TLRY

The company's powerful growth isn't only due to its coronavirus vaccine.

Why Pfizer Shot Higher Today

Pfizer's vaccine initially protects people 100% of the time against hospitalization, but that falls to low 90% and mid-to-high 80% after six months, Bourla said

Pfizer's CEO says Covid vaccine effectiveness drops to 84% after six months

Based on its earnings report, Pfizer (PFE) raised estimated sales of its Covid-19 vaccine to $33.5 billion for 2021, reflecting a 30% increase as Delta sweeps through nations, reports The Wall Street Journal. The biopharmaceutical giant is one of many major players reporting profitable earnings for the last quarter as these mega-caps continue to outperform.

Pfizer Reports Positive Earnings, Raises Forecasted Sales of Vaccine

A third dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine can "strongly" boost protection against the delta variant beyond the protection afforded by the standard two doses. Pfizer's new data suggest that antibody levels against the delta variant in people ages 18 to 55 who receive a third dose of vaccine are greater than five-fold than following a second dose.

Third Dose Of Pfizer-BioNTech's COVID-19 Vaccine Boosts Protection Against Delta Variant, New Data Reveals

Pfizer Inc., (NYSE: PFE) announced that the company sold Covid-19 jabs worth $7.8 billion in the second quarter. In addition, the company raised its full-year 2021 sales estimates from the vaccine from $26 billion to $33.5 billion.

Here's how much money Pfizer collected from COVID-19 vaccine shots in Q2

Costco

Dollar General

Lockheed Martin

Procter & Gamble

Rio Tinto plc Sponsored

These defensive stocks are worth adding to your portfolio as the market looks overvalued and a sharp correction seems likely. The post 7 Defensive Stocks to Buy for an Upcoming Market Crash appeared first on InvestorPlace.

7 Defensive Stocks to Buy for an Upcoming Market Crash

Pfizer expects to deliver 2.1 billion doses of its COVID-19 vaccine in 2021, with plans to manufacture a total of 3 billion by the end of 2021.

Pfizer sees COVID-19 vaccine revenue rise, expects to deliver 2.1 billion doses in 2021

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.

Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine

Pfizer Inc. (NYSE: PFE) shares were trading about 2.1% higher at $42.99 per share after the company reported better-than-expected Q2 EPS and sales results. The company also raised its full-year 2021 earnings per share guidance and sales guidance above analyst estimates.

Why Pfizer And BioNTech Shares Are Moving Higher Today

Pfizer sold a staggering $7.8 billion worth of coronavirus jabs during the second quarter — and predicted its profits will continue to explode as the Delta variant spurs fresh demand for booster shots.

Pfizer sold $7.8B in COVID vaccines in 2Q, predicts more Delta-driven demand

Here's What the Surge in COVID's Delta Variant Could Mean for Pfizer's Stock

The Pfizer-BioNTech vaccine is on track to bring in more revenue in a single year than any other drug in history.

Pfizer Says It Will Now Sell $33.5 Billion of Its Covid-19 Vaccine This Year

Pfizer Inc. (NYSE:PFE) reported second-quarter earnings of $1.07 per share, which was better than the estimates of 98 cents. The company also raised full-year guidance to $3.95 to $4.05.

Pfizer Crushes Earnings, But Will The Stock Rally?

Pfizer's Q2 earnings and revenue exceeded analysts' expectations.

Pfizer Q2 2021 Earnings Report Recap

Pfizer Inc. said Wednesday that a third dose of its COVID-19 vaccine likely provides further protection against the delta variant, which is more infectious and thought to be driving the recent surge in cases, hospitalizations, and deaths in the U.S. The drug maker announced the news as part of its second-quarter earnings, saying that an additional dose of its two-dose COVID-19 vaccine series produced neutralizing antibody titers against delta that are 5 times higher than getting two doses in younger people and 11 times higher than getting two doses in older people. Pfizer did not provide any additional information at this time.

Pfizer shares limited data about its COVID-19 booster candidate, says it ups protection against the delta variant

Shares of Pfizer Inc. were down 0.6% in premarket trading on Wednesday after the company clocked another nearly $8 billion in revenue for the COVID-19 vaccine it developed with BioNTech SE . Pfizer now expects that the vaccine will generate $33.5 billion in revenue this year.

Pfizer's COVID-19 vaccine generated $7.8 billion in revenue in the second quarter

Shares of Pfizer (NYSE:PFE) moved higher by 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 37.18% over the past year to $1.07, which beat the estimate of $0.96.

Recap: Pfizer Q2 Earnings

Pfizer Inc (NYSE: PFE) reports Q2 adjusted EPS of $1.07, well ahead of the consensus of $0.96 and 73% Y/Y higher from $0.62 posted a year ago.  The Company achieved Q2 revenues of $18.9 billion, +92% Y/Y, reflecting operational growth of $8.5 billion, or +86%, surpassing the Wall Street estimate of $18.4 billion.

Pfizer Q2 Results Beat Wall Street Expectations; Expects $33B From COVID-19 Vax Sales In 2021

Pfizer said Wednesday it is raising the 2021 sales forecast of its Covid-19 vaccine to $33.5 billion from $26 billion.

Pfizer sells $7.8 billion in Covid shots in the Q2, raises 2021 guidance on vaccine sales

Pfizer lifts earnings and revenue guidance for the year

News for Pfizer Stock (PFE)